Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
3.74
0.70 (23.03%)
At close: Aug 15, 2025, 2:36 PM
23.03% (1D)
| Bid | 3.72 |
| Market Cap | 134.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.77M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -1.97 |
| Forward PE | -2.08 |
| Analyst | Buy |
| Ask | 3.74 |
| Volume | 571,075 |
| Avg. Volume (20D) | 1,265,819 |
| Open | 3.00 |
| Previous Close | 3.04 |
| Day's Range | 3.00 - 3.75 |
| 52-Week Range | 1.00 - 4.69 |
| Beta | 0.37 |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 hour ago
Immuneering shares are trading higher after the co...
Unlock content with
Pro Subscription
1 month ago
+11.25%
Immuneering shares are trading higher after the company announced granted a U.S. composition of matter patent for Atebimetinib.
